Market research
MMIA.F MEI Pharma, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 10.67
- Dividend yield
- 0.0%
- Beta
- 1.02
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US55279B2025
- Market cap
- 29M
- P/E ratio
- Not available
- Analyst target
- 10.67
- Dividend yield
- 0.0%
- Beta
- 1.02
About
About MEI Pharma, Inc
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MMIA.F discussion.
5 years, 5 months ago
MEI Pharma, Inc is currently in a long term downtrend where the price is trading 12.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.4.
MEI Pharma, Inc's total revenue rose by 809.4% to $9M since the same quarter in the previous year.
Its net income has increased by 43.3% to $-11M since the same quarter in the previous year.
Finally, its free cash flow grew by 138.1% to $4M since the same quarter in the previous year.
Based on the above factors, MEI Pharma, Inc gets an overall score of 4/5.